Fig. 2.
Representative tracing (A and B) and group data (C) showing the sympathoexcitatory responses to ICV PGE2 were significantly diminished by ICV pretreatment with EP3 receptor antagonist L-798106 (10 nmol) but not affected by ICV pretreatment with the EP4 receptor antagonist L-161982 (10 nmol) or the EP1 receptor antagonist SC-19220 (10 nmol). Arrows indicate time of PGE2 injections. n, Number of interventions. *P < 0.05 vs. Veh; †P < 0.05 vs. Veh + PGE2.